Staidson Beijing Biopharma (300204) — Tangible Net Worth Ratio
Staidson Beijing Biopharma (300204) has a Tangible Net Worth Ratio of 70.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥236.85 Million) from net assets (CN¥794.92 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Staidson Beijing Biopharma current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Staidson Beijing Biopharma Tangible Net Worth Ratio (2007–2025)
This chart shows how Staidson Beijing Biopharma's Tangible Net Worth Ratio has changed across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 70.2%, reflecting net assets of CN¥794.92 Million with intangible assets of CN¥236.85 Million CNY. See 300204 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Staidson Beijing Biopharma (2007–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Staidson Beijing Biopharma from 2007 to 2025, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Staidson Beijing Biopharma market cap and net worth.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 72.4% | CN¥806.72 Million | CN¥222.33 Million | CN¥1.27 Billion | ▼ -10.9 pp |
| 2024 | 83.4% | CN¥916.76 Million | CN¥152.34 Million | CN¥1.15 Billion | ▼ -7.1 pp |
| 2023 | 90.4% | CN¥1.02 Billion | CN¥97.62 Million | CN¥1.33 Billion | ▼ -1.6 pp |
| 2022 | 92.1% | CN¥1.35 Billion | CN¥107.22 Million | CN¥1.67 Billion | ▼ -2.3 pp |
| 2021 | 94.4% | CN¥1.55 Billion | CN¥87.34 Million | CN¥1.83 Billion | ▲ +0.9 pp |
| 2020 | 93.5% | CN¥1.59 Billion | CN¥103.10 Million | CN¥1.86 Billion | ▼ -3.4 pp |
| 2019 | 96.9% | CN¥1.64 Billion | CN¥50.34 Million | CN¥1.86 Billion | ▼ -1.3 pp |
| 2018 | 98.2% | CN¥2.46 Billion | CN¥44.70 Million | CN¥2.77 Billion | ▼ -0.2 pp |
| 2017 | 98.3% | CN¥2.21 Billion | CN¥36.47 Million | CN¥2.63 Billion | ▲ +0.3 pp |
| 2016 | 98.1% | CN¥1.92 Billion | CN¥36.93 Million | CN¥2.35 Billion | ▲ +0.3 pp |
| 2015 | 97.8% | CN¥1.68 Billion | CN¥37.39 Million | CN¥2.07 Billion | ▲ +1.9 pp |
| 2014 | 95.9% | CN¥1.51 Billion | CN¥62.17 Million | CN¥1.81 Billion | ▲ +0.7 pp |
| 2013 | 95.2% | CN¥1.31 Billion | CN¥62.61 Million | CN¥1.57 Billion | ▲ +0.4 pp |
| 2012 | 94.9% | CN¥1.24 Billion | CN¥63.65 Million | CN¥1.43 Billion | ▼ -3.0 pp |
| 2011 | 97.9% | CN¥1.10 Billion | CN¥23.52 Million | CN¥1.15 Billion | ▲ +14.1 pp |
| 2010 | 83.7% | CN¥166.23 Million | CN¥27.06 Million | CN¥264.88 Million | ▲ +7.4 pp |
| 2009 | 76.3% | CN¥119.72 Million | CN¥28.34 Million | CN¥148.75 Million | ▲ +26.2 pp |
| 2008 | 50.1% | CN¥62.82 Million | CN¥31.33 Million | CN¥92.07 Million | ▲ +8.8 pp |
| 2007 | 41.4% | CN¥33.87 Million | CN¥19.86 Million | CN¥82.22 Million | — |